Galmed pharmaceuticals announces dosing of first subject in first in human phase 1 trial of amilo-5mer

Tel aviv, israel, march 16, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the first-in-human phase i clinical trial evaluating amilo-5mer for the treatment of chronic inflammatory diseases.
GLMD Ratings Summary
GLMD Quant Ranking